Table II.
Significant results relevant to pathways described
| Dataset | Metabolite | Model | Outcome | Direction of association |
|---|---|---|---|---|
| Lipid mediators | AA | Draw 1 | PWT | – |
| Lipid mediators | AEA | Draw 1 | PWT | – |
| Lipid mediators | N-oleoylethanolamide | Draw 1 | PWT | – |
| Lipid mediators | Adrenoyl-ethanolamide | Draw 3 – Draw 1 | Individual response to SET | – |
| Lipid mediators | AA | Draw 3 – Draw 1 | Individual response to SET | + |
| Lipid mediators | AEA | (Draw 4 – Draw 3) – (Draw 2 – Draw 1) | Individual response to SET | – |
| Lipid mediators | AA | (Draw 4 – Draw 3) – (Draw 2 – Draw 1) | Individual response to SET | + |
AA, Arachidonic acid; AEA, acyl ethanolamide; PWT, peak walking time; SET, supervised exercise therapy.
Metabolites were analyzed in relationship to pretherapy log(PWT) and the standardized measure of individual improvement in PWT for each of the three data sets using five models: general linear model, elastic net, lasso, random Forest, and support vector machine. Metabolites of significant interest were classified as achieving nominal significance on two or more models or experiment wide significance on one model. Multiple testing correction threshold was set at a false discovery rate of 0.05 for each model and for each of the three datasets. This table includes only significant results of select metabolites.